Affinity Asset Advisors, LLC — 13F Holdings & Portfolio
CIK 1773195 · latest 13F-HR filed 2026-05-14
Affinity Asset Advisors, LLC manages $1.94B in 13F-reported U.S. long-equity assets across 105 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are SPY (6.72%), APGE (5.59%), XENE (5.03%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 20 new positions, exited 11, added to 34, and trimmed 33.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$1.94B
Long-equity book
105
Distinct positions
2026-03-31
Filed 2026-05-14
+20 / −11 / ↑34 / ↓33
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ERASCA INC$72.1M +496.7%
- XENON PHARMACEUTICALS INC$41.4M +73.9%
- ROIVANT SCIENCES LTD$40.7M +110.2%
- CENTESSA PHARMACEUTICALS PLC$40.6M +270.2%
- ANAPTYSBIO INC$30.6M +141.8%
Top Trims
- WAVE LIFE SCIENCES LTD-$35.7M -77.9%
- ABIVAX SA-$23.0M -33.8%
- TAYSHA GENE THERAPIES INC-$13.7M -75.4%
- BRIDGEBIO PHARMA INC-$13.3M -54.5%
- ESTABLISHMENT LABS HLDGS INC-$8.9M -61.0%
New Positions
- ENLIVEN THERAPEUTICS INC$23.0M
- HELIX ACQUISITION CORP III$12.7M
- DAMORA THERAPEUTICS INC$11.7M
- ALTO NEUROSCIENCE INC$11.2M
- TYRA BIOSCIENCES INC$9.9M
Exited Positions
- VENTYX BIOSCIENCES INC$58.6M
- TRAVERE THERAPEUTICS INC$10.0M
- TANGO THERAPEUTICS INC$8.9M
- ARCUS BIOSCIENCES INC$7.1M
- AVADEL PHARMACEUTICALS PLC$5.4M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | STATE STR SPDR S&P 500 ETF T Put | SPY | 78462F103 | $130.1M | 6.72% | 200,000 | SH |
| 2 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $108.2M | 5.59% | 1,284,926 | SH |
| 3 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $97.4M | 5.03% | 1,675,000 | SH |
| 4 | ERASCA INC | ERAS | 29479A108 | $86.6M | 4.47% | 5,350,000 | SH |
| 5 | INSMED INC | INSM | 457669307 | $78.5M | 4.05% | 480,000 | SH |
| 6 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $77.6M | 4.01% | 2,800,000 | SH |
| 7 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $64.5M | 3.33% | 1,279,134 | SH |
| 8 | CENTESSA PHARMACEUTICALS PLC | CNTA | 152309100 | $55.6M | 2.87% | 1,400,000 | SH |
| 9 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $54.8M | 2.83% | 170,000 | SH |
| 10 | ANAPTYSBIO INC | ANAB | 032724106 | $52.1M | 2.69% | 940,000 | SH |
| 11 | ALKERMES PLC | ALKS | G01767105 | $47.7M | 2.47% | 1,350,000 | SH |
| 12 | CYTOKINETICS INC | CYTK | 23282W605 | $46.2M | 2.38% | 700,483 | SH |
| 13 | ABIVAX SA | ABVX | 00370M103 | $45.1M | 2.33% | 405,000 | SH |
| 14 | TEVA PHARMACEUTICAL INDS LTD | TEVA | 881624209 | $42.2M | 2.18% | 1,400,000 | SH |
| 15 | ARCELLX INC | ACLX | 03940C100 | $41.7M | 2.15% | 362,764 | SH |
| 16 | MODERNA INC Call | MRNA | 60770K107 | $40.6M | 2.10% | 800,000 | SH |
| 17 | NUVALENT INC | NUVL | 670703107 | $30.7M | 1.59% | 300,000 | SH |
| 18 | TERNS PHARMACEUTICALS INC | TERN | 880881107 | $29.7M | 1.53% | 562,631 | SH |
| 19 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $29.4M | 1.52% | 350,000 | SH |
| 20 | LEXEO THERAPEUTICS INC | LXEO | 52886X107 | $29.0M | 1.50% | 5,050,211 | SH |
| 21 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $28.9M | 1.49% | 750,000 | SH |
| 22 | MADRIGAL PHARMACEUTICALS INC | MDGL | 558868105 | $28.8M | 1.49% | 55,000 | SH |
| 23 | SUTRO BIOPHARMA INC | STRO | 869367201 | $26.6M | 1.38% | 1,069,519 | SH |
| 24 | FORTE BIOSCIENCES INC | FBRX | 34962G208 | $26.2M | 1.35% | 1,011,890 | SH |
| 25 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $24.5M | 1.27% | 499,673 | SH |
| 26 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $23.9M | 1.23% | 2,000,172 | SH |
| 27 | OVID THERAPEUTICS INC | OVID | 690469101 | $23.6M | 1.22% | 10,636,318 | SH |
| 28 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $23.0M | 1.19% | 586,904 | SH |
| 29 | ASCENDIS PHARMA A/S | ASND | 04351P101 | $21.7M | 1.12% | 95,000 | SH |
| 30 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $20.3M | 1.05% | 750,000 | SH |
| 31 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $20.0M | 1.03% | 1,340,840 | SH |
| 32 | BRISTOL-MYERS SQUIBB CO Call | BMY | 110122108 | $18.2M | 0.94% | 300,000 | SH |
| 33 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $18.1M | 0.94% | 172,125 | SH |
| 34 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $15.9M | 0.82% | 500,000 | SH |
| 35 | ZURA BIO LTD | ZURA | G9TY5A101 | $15.3M | 0.79% | 2,564,303 | SH |
| 36 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $15.0M | 0.77% | 967,620 | SH |
| 37 | SAVARA INC | SVRA | 805111101 | $13.7M | 0.71% | 2,512,153 | SH |
| 38 | OMEROS CORP | — | 682143AK8 | $13.2M | 0.68% | 6,525,000 | PRN |
| 39 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $13.2M | 0.68% | 3,164,582 | SH |
| 40 | HELIX ACQUISITION CORP III | HLXC | G4444S107 | $12.7M | 0.66% | 1,250,000 | SH |
| 41 | ARROWHEAD PHARMACEUTICALS IN | ARWR | 04280A100 | $12.5M | 0.65% | 200,000 | SH |
| 42 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $11.7M | 0.60% | 450,000 | SH |
| 43 | EUPRAXIA PHARMACEUTICALS INC | EPRX | 29842P105 | $11.5M | 0.59% | 1,589,005 | SH |
| 44 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $11.2M | 0.58% | 500,000 | SH |
| 45 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $11.1M | 0.58% | 150,000 | SH |
| 46 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $11.1M | 0.57% | 781,260 | SH |
| 47 | BELITE BIO INC | BLTE | 07782B104 | $10.4M | 0.54% | 65,000 | SH |
| 48 | WAVE LIFE SCIENCES LTD | WVE | Y95308105 | $10.2M | 0.52% | 1,401,727 | SH |
| 49 | VERA THERAPEUTICS INC | VERA | 92337R101 | $10.1M | 0.52% | 250,000 | SH |
| 50 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $9.9M | 0.51% | 257,512 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $1.94B | 105 | 0001315863-26-000411 |
| 2025-12-31 | 2026-02-13 | $1.76B | 95 | 0001315863-26-000153 |
| 2025-09-30 | 2025-11-13 | $1.15B | 96 | 0001999371-25-017685 |